688331 荣昌生物
已收盘 12-05 15:00:01
资讯
新帖
简况
医药股普遍回暖 荣昌生物(09995)涨4.26% 交银国际料明年内地医药板块稳中向好态势延续
金吾财讯 · 12-04
医药股普遍回暖 荣昌生物(09995)涨4.26% 交银国际料明年内地医药板块稳中向好态势延续
荣昌生物(09995)涨逾4%终结三连阴 此前获贝莱德大手增持 机构指其正快速向盈亏平衡点靠拢
金吾财讯 · 12-04
荣昌生物(09995)涨逾4%终结三连阴 此前获贝莱德大手增持 机构指其正快速向盈亏平衡点靠拢
核心高管精准减持“撤离”，控股股东却被“锁仓”，荣昌生物何时才能盈利？｜创新药观察
华夏时报网 · 12-03
核心高管精准减持“撤离”，控股股东却被“锁仓”，荣昌生物何时才能盈利？｜创新药观察
【券商聚焦】中泰证券维持荣昌生物(09995)“增持”评级 指其正处在商业化能力加速兑现的通道上
金吾财讯 · 12-03
【券商聚焦】中泰证券维持荣昌生物(09995)“增持”评级 指其正处在商业化能力加速兑现的通道上
荣昌生物（688331）披露预计2026-2028年度日常关联交易议案，12月02日股价下跌2.11%
证券之星 · 12-02
荣昌生物（688331）披露预计2026-2028年度日常关联交易议案，12月02日股价下跌2.11%
荣昌生物遭贝莱德减持18.55万股 每股作价约81.64港元
新浪港股 · 12-01
荣昌生物遭贝莱德减持18.55万股 每股作价约81.64港元
贝莱德减持荣昌生物(09995)18.55万股 每股作价约81.64港元
智通财经 · 11-28
贝莱德减持荣昌生物(09995)18.55万股 每股作价约81.64港元
港股异动 | 荣昌生物(09995)午后涨超7% 泰它西普快速放量 维迪西妥联合免疫疗效优异
智通财经 · 11-27
港股异动 | 荣昌生物(09995)午后涨超7% 泰它西普快速放量 维迪西妥联合免疫疗效优异
荣昌生物(09995)股东将股票由法国巴黎银行转入香港上海汇丰银行 转仓市值8.96亿港元
智通财经 · 11-27
荣昌生物(09995)股东将股票由法国巴黎银行转入香港上海汇丰银行 转仓市值8.96亿港元
荣昌生物涨5.43%，东海证券三周前给出“买入”评级
证券之星 · 11-26
荣昌生物涨5.43%，东海证券三周前给出“买入”评级
生物医药股悉数走强 荣昌生物(09995)涨6.65% 机构指医药行业近期震荡调整后估值已回落至相对低位
金吾财讯 · 11-26
生物医药股悉数走强 荣昌生物(09995)涨6.65% 机构指医药行业近期震荡调整后估值已回落至相对低位
荣昌生物（688331）披露预计2026-2028年度日常关联交易，11月24日股价上涨2.27%
证券之星 · 11-24
荣昌生物（688331）披露预计2026-2028年度日常关联交易，11月24日股价上涨2.27%
生物医药股全线下跌 荣昌生物(09995)、金斯瑞生物科技(01548)跌超6%
金吾财讯 · 11-21
生物医药股全线下跌 荣昌生物(09995)、金斯瑞生物科技(01548)跌超6%
每周股票复盘：荣昌生物（688331）Q3营收6.2亿环比增8.7%
证券之星 · 11-16
每周股票复盘：荣昌生物（688331）Q3营收6.2亿环比增8.7%
荣昌生物（688331）披露2022年A股限制性股票激励计划B类权益预留授予第一个归属期第一次归属结果暨股份上市公告，11月13日股价上涨3.37%
中金财经 · 11-13
荣昌生物（688331）披露2022年A股限制性股票激励计划B类权益预留授予第一个归属期第一次归属结果暨股份上市公告，11月13日股价上涨3.37%
【机构调研记录】诺安基金调研荣昌生物、阿拉丁
证券之星 · 11-13
【机构调研记录】诺安基金调研荣昌生物、阿拉丁
【券商聚焦】浦银国际维持荣昌生物(09995)“持有”评级 指3Q25继续延续此前减亏趋势
金吾财讯 · 11-05
【券商聚焦】浦银国际维持荣昌生物(09995)“持有”评级 指3Q25继续延续此前减亏趋势
荣昌生物（688331）披露作废部分2022年A股限制性股票激励计划已授予尚未归属的限制性股票，11月4日股价下跌1.18%
证券之星 · 11-04
荣昌生物（688331）披露作废部分2022年A股限制性股票激励计划已授予尚未归属的限制性股票，11月4日股价下跌1.18%
小摩：升荣昌生物(09995)目标价至77港元 评级升至中性
智通财经 · 11-04
小摩：升荣昌生物(09995)目标价至77港元 评级升至中性
交银国际：升荣昌生物(09995)目标价至112港元 维持“买入”评级
智通财经 · 11-04
交银国际：升荣昌生物(09995)目标价至112港元 维持“买入”评级
加载更多
公司概况
公司名称：
荣昌生物制药(烟台)股份有限公司
所属行业：
医药制造业
上市日期：
2022-03-31
主营业务：
荣昌生物制药(烟台)股份有限公司的主营业务是抗体药物偶联物（ADC）、抗体融合蛋白、单抗及双抗等治疗性抗体药物的研发、生产和销售。公司的主要产品是泰它西普、维迪西妥单抗、RC28、RC88、RC148、RC278、RC288。泰它西普发明专利先后获得中国、美国、欧洲等国家和地区的授权，得到了国家“十一五”、“十二五”、“十三五”期间“重大新药创制”科技重大专项支持。
发行价格：
48.00
{"stockData":{"symbol":"688331","market":"SH","secType":"STK","nameCN":"荣昌生物","latestPrice":96.45,"timestamp":1764918001000,"preClose":95.37,"halted":0,"volume":3324393,"delay":0,"changeRate":0.0113,"floatShares":162000000,"shares":564000000,"eps":-1.6811,"marketStatus":"已收盘","change":1.08,"latestTime":"12-05 15:00:01","open":95.59,"high":96.66,"low":93.5,"amount":317000000,"amplitude":0.0331,"askPrice":96.46,"askSize":31,"bidPrice":96.45,"bidSize":12,"shortable":0,"etf":0,"ttmEps":-1.6811,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":5,"adr":0,"adjPreClose":95.37,"symbolType":"stock_kcb","openAndCloseTimeList":[[1764898200000,1764905400000],[1764910800000,1764918000000]],"highLimit":104.91,"lowLimit":85.83,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":563710243,"isCdr":false,"pbRate":23.43,"roa":"--","roe":"--","epsLYR":-2.73,"committee":0.088825,"marketValue":54370000000,"turnoverRate":0.0205,"status":0,"afterMarket":{"amount":0,"volume":0,"close":96.45,"buyVolume":0,"sellVolume":0,"time":1764920037768,"indexStatus":"已收盘 12-05 15:30:00","preClose":95.37},"hkstockBrief":{"symbol":"09995","market":"HK","secType":"STK","nameCN":"荣昌生物","latestPrice":88.35,"timestamp":1764922148010,"preClose":89.7,"halted":0,"volume":2150000,"delay":0,"premium":"-16.81"},"floatMarketCap":15656000000},"requestUrl":"/m/hq/s/688331","defaultTab":"news","newsList":[{"id":"2588074906","title":"医药股普遍回暖 荣昌生物(09995)涨4.26% 交银国际料明年内地医药板块稳中向好态势延续","url":"https://stock-news.laohu8.com/highlight/detail?id=2588074906","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588074906?lang=zh_cn&edition=full","pubTime":"2025-12-04 10:58","pubTimestamp":1764817092,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药股普遍回暖，荣昌生物 涨4.26%，康方生物涨3.89%，金斯瑞生物科技涨3.11%，康诺亚-B涨2.95%，科伦博泰生物-B涨2.45%，诺诚健华涨1.79%，药明生物涨1.63%，泰格医药涨1.38%，药明康德涨1.33% 。交银国际发表报告指，予内地医药行业领先评级。如该行此前预期，内地医药行业2025年迎来关键转折。2026年，该行认为板块稳中向好态势延续，但影响市场表现的核心因素或呈分化态势。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1970883","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1610","LU2488822045.USD","BK1587","02269","LU0588546209.SGD","LU0823426308.USD","LU0417516571.SGD","LU1961090484.USD","LU0634319403.HKD","BK1574","LU0307460666.USD","LU2399975544.HKD","LU0359202008.SGD","LU0181495838.USD","06990","09969","LU0326950275.SGD","LU0516423091.SGD","LU0856984785.SGD","09939","02162","LU1688375341.USD","LU1880383366.USD","BK1589","HK0000320264.USD","LU2242644610.SGD","LU0359201612.USD","LU1046422090.SGD","LU0516422952.EUR","BK0239","LU1720050803.USD","LU0561508036.HKD","BK1161","09995","LU2148510915.USD","01548","LU2039709279.SGD","LU0052750758.USD","03347","LU2328871848.SGD","BK1515","LU2476274720.SGD","BK1141","688331","09926","03329","IE00BPRC5H50.USD","LU0819121731.USD","159938","02359"],"gpt_icon":0},{"id":"2588407102","title":"荣昌生物(09995)涨逾4%终结三连阴 此前获贝莱德大手增持 机构指其正快速向盈亏平衡点靠拢","url":"https://stock-news.laohu8.com/highlight/detail?id=2588407102","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588407102?lang=zh_cn&edition=full","pubTime":"2025-12-04 10:33","pubTimestamp":1764815583,"startTime":"0","endTime":"0","summary":"金吾财讯 | 荣昌生物(09995)早盘股价反弹回升，终结此前日线图三连阴，截至发稿，报88港元，涨4.2%，成交额1.11亿港元。消息面上，根据香港联交所11月28日披露的文件，贝莱德(BlackRock, Inc.)于11月24日以每股均价82.9384港元增持461.3万股H股股份，价值约3.83亿港元。增持后，贝莱德最新持股数目为1,057.95万股股份，好仓比例由2.86%升至5.07%。中泰证券研报指，荣昌生物正处在商业化能力加速兑现的通道上，通过高效的运营和精准的投入，公司正快速向盈亏平衡点靠拢。维持“增持”评级。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1970881","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BVYPNV92.GBP","LU1599440770.SGD","LU2430703251.USD","LU2264538146.SGD","IE00B64PRP62.GBP","LU1481011671.HKD","LU2505996509.AUD","BK1161","LU1366333091.USD","LU2328871848.SGD","BK4581","IE00BVYPNW00.USD","IE00B3QW5Z07.USD","BK4585","BK1583","LU1509826696.USD","BK4135","BK4567","LU0157215616.USD","LU0208291251.USD","LU0648001328.SGD","BK4504","LU2505996681.GBP","09995","LU0320765489.SGD","LU1201861249.SGD","LU2488822045.USD","BK4588","IE00B3PB1722.GBP","IE00BGHQF631.EUR","IE00BDGV0183.EUR","LU0772969993.USD","LU0130102774.USD","LU1280957306.USD","BLK","LU0640476718.USD","LU1064131003.USD","IE00B42XCP33.USD","LU0980610538.SGD","IE00BGHQF748.EUR","BK1574","LU0742537680.HKD","LU0731783394.SGD","LU1670627923.USD","LU0070302665.USD","BK4534","BK4533","688331","LU1064130708.USD","LU1969619763.USD"],"gpt_icon":0},{"id":"2588045496","title":"核心高管精准减持“撤离”，控股股东却被“锁仓”，荣昌生物何时才能盈利？｜创新药观察","url":"https://stock-news.laohu8.com/highlight/detail?id=2588045496","media":"华夏时报网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588045496?lang=zh_cn&edition=full","pubTime":"2025-12-03 20:23","pubTimestamp":1764764612,"startTime":"0","endTime":"0","summary":"2025年12月3日，一则荣昌生物制药（烟台）股份有限公司（下称“荣昌生物”，股票代码688331.SH、9995.HK）疑似减持受限的消息引起《华夏时报》记者注意。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512033581742820.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512033581742820.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159992","BK0239","09995","BK1574","LU1064130708.USD","LU1064131003.USD","BK1583","LU1969619763.USD","LU2148510915.USD","LU2328871848.SGD","LU2488822045.USD","BK1161","688331","06978"],"gpt_icon":0},{"id":"2588090548","title":"【券商聚焦】中泰证券维持荣昌生物(09995)“增持”评级 指其正处在商业化能力加速兑现的通道上","url":"https://stock-news.laohu8.com/highlight/detail?id=2588090548","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588090548?lang=zh_cn&edition=full","pubTime":"2025-12-03 14:26","pubTimestamp":1764743192,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中泰证券研报指，荣昌生物 营业总收入17.20亿元；归母净利润-5.51亿元，亏损收窄，主要得益于核心产品的持续放量、销售和管理费用的有效控制，以及泰它西普海外临床费用转由合作方承担后带来的研发支出下降；销售毛利率84.27%，+4.52个百分点，研发费用8.91亿元。荣昌生物正处在商业化能力加速兑现的通道上，通过高效的运营和精准的投入，公司正快速向盈亏平衡点靠拢。维持“增持”评级。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1970822","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600918","09995","688331"],"gpt_icon":0},{"id":"2588960059","title":"荣昌生物（688331）披露预计2026-2028年度日常关联交易议案，12月02日股价下跌2.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588960059","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588960059?lang=zh_cn&edition=full","pubTime":"2025-12-02 22:17","pubTimestamp":1764685032,"startTime":"0","endTime":"0","summary":"截至2025年12月2日收盘，荣昌生物报收于93.23元，较前一交易日下跌2.11%，最新总市值为525.55亿元。该股当日开盘94.0元，最高95.97元，最低92.96元，成交额达2.55亿元，换手率为1.67%。公司近日发布公告称，荣昌生物制药（烟台）股份有限公司于2025年12月2日召开2025年第三次临时股东会，会议审议通过《关于预计2026-2028年度日常关联交易的议案》及《关于修订公司部分治理制度的议案》下的四项子议案。出席会议的股东共180人，代表表决权股份占公司总表决权的47.5817%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200039616.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2328871848.SGD","LU1969619763.USD","09995","LU2148510915.USD","BK0239","LU1064130708.USD","LU1064131003.USD","LU2488822045.USD","688331","BK1574","BK1583","BK1161"],"gpt_icon":0},{"id":"2588115737","title":"荣昌生物遭贝莱德减持18.55万股 每股作价约81.64港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2588115737","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588115737?lang=zh_cn&edition=full","pubTime":"2025-12-01 08:51","pubTimestamp":1764550260,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 香港联交所最新资料显示，11月25日，贝莱德减持荣昌生物（09995）18.55万股，每股作价81.6411港元，总金额约为1514.44万港元。减持后最新持股数目约为1041.11万股，最新持股比例为4.99%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-12-01/doc-infzhauh5174148.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00B3QW5Z07.USD","688331","IE00B42XCP33.USD","IE00B3PB1722.GBP","LU2505996681.GBP","BK4585","IE00B64PRP62.GBP","LU1481011671.HKD","LU0070302665.USD","09995","LU1064131003.USD","LU1366333091.USD","IE00BVYPNV92.GBP","LU1989771016.USD","BK1574","LU2592432038.USD","LU2328871848.SGD","BK1583","LU1291159041.SGD","BLK","LU0130102774.USD","BK4581","LU0731783048.USD","BK4588","IE00BGHQF631.EUR","LU1988902786.USD","LU0980610538.SGD","LU1969619763.USD","LU1599440770.SGD","BK4567","LU0640476718.USD","BK0239","BK1161","BK4135","IE00BDGV0183.EUR","LU0742537680.HKD","LU1064130708.USD","LU1481011911.USD","LU2264538146.SGD","LU2430703095.HKD","LU1074936037.SGD","LU2430703251.USD","IE00BVYPNW00.USD","LU0648001328.SGD","LU2488822045.USD","LU2430703178.SGD","LU0157215616.USD","LU0731783394.SGD","LU1064131342.USD","LU2505996509.AUD"],"gpt_icon":0},{"id":"2586841784","title":"贝莱德减持荣昌生物(09995)18.55万股 每股作价约81.64港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2586841784","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586841784?lang=zh_cn&edition=full","pubTime":"2025-11-28 20:04","pubTimestamp":1764331478,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，11月25日，贝莱德减持荣昌生物(09995)18.55万股，每股作价81.6411港元，总金额约为1514.44万港元。减持后最新持股数目约为1041.11万股，最新持股比例为4.99%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375339.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BVYPNV92.GBP","LU0130102774.USD","09995","LU0742537680.HKD","LU1670627923.USD","IE00B3QW5Z07.USD","BK4533","LU2328871848.SGD","LU1280957306.USD","LU0070302665.USD","LU2505996509.AUD","IE00B64PRP62.GBP","BLK","LU2430703178.SGD","LU1599440770.SGD","LU1074936037.SGD","688331","LU0208291251.USD","LU2264538146.SGD","BK4504","IE00B3PB1722.GBP","BK1574","LU0980610538.SGD","LU1988902786.USD","BK4535","BK4567","LU0320765489.SGD","LU0640476718.USD","LU2148510915.USD","LU0648001328.SGD","IE00BDGV0183.EUR","LU1670628061.USD","LU0772969993.USD","LU1989771016.USD","LU2430703251.USD","BK4585","LU1509826696.USD","BK1161","LU0731783048.USD","LU1064131342.USD","LU2505996681.GBP","LU1969619763.USD","IE00BGHQF748.EUR","IE00BVYPNW00.USD","LU2592432038.USD","LU0731783394.SGD","BK4135","LU1201861249.SGD","LU1291159041.SGD","LU1064131003.USD"],"gpt_icon":0},{"id":"2586219903","title":"港股异动 | 荣昌生物(09995)午后涨超7% 泰它西普快速放量 维迪西妥联合免疫疗效优异","url":"https://stock-news.laohu8.com/highlight/detail?id=2586219903","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586219903?lang=zh_cn&edition=full","pubTime":"2025-11-27 13:39","pubTimestamp":1764221992,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，荣昌生物午后涨超7%，截至发稿，涨6.39%，报90.75港元，成交额3.19亿港元。甬兴证券发布研报称，维迪西妥联合免疫疗效优异，标志着尿路上皮癌治疗格局重大变革。中信建投发布研报称，2025年，核心产品泰它西普新增适应症获批后快速放量，维迪西妥单抗联合治疗方案数据优异，同时RC28的DME适应症上市申请获受理；在研管线中RC148获突破性疗法认定，临床数据持续验证价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374353.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1161","688331","LU2488822045.USD","BK1574","LU1064131003.USD","BK0239","LU1064130708.USD","LU1969619763.USD","LU2148510915.USD","09995","LU2328871848.SGD"],"gpt_icon":0},{"id":"2586291653","title":"荣昌生物(09995)股东将股票由法国巴黎银行转入香港上海汇丰银行 转仓市值8.96亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2586291653","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586291653?lang=zh_cn&edition=full","pubTime":"2025-11-27 08:31","pubTimestamp":1764203488,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，11月26日，荣昌生物(09995)股东将股票由法国巴黎银行转入香港上海汇丰银行，转仓市值8.96亿港元，占比5.29%。建银国际近日发布研报称，将荣昌生物目标价，由110港元调高9%至120港元，维持“跑赢大市”的投资评级。建银国际表示，基本上维持对荣昌生物2025年/2026年/2027年总营收的预测不变，分别为28亿元人民币/34亿元人民币/46亿元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374227.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03143","BK1601","LU0516422952.EUR","LU0310800965.SGD","LU0516422440.USD","09995","HSHD.SI","LU0516423174.USD","LU0516423091.SGD","LU1064130708.USD","BK0239","LU1267930227.SGD","HSBA.UK","BK1574","LU0516422366.SGD","LU1064131003.USD","688331","BK4588","LU0164880469.USD","LU0417516738.SGD","00005","LU1481107354.HKD","BK1572","BK4521","BK1231","LU2236285917.USD","LU2328871848.SGD","LU0540923850.HKD","BK1610","BK4585","HSBC","LU0052756011.USD","BK1161","LU0149721374.USD","LU2488822045.USD","LU0348735423.USD","LU2148510915.USD","LU0128525689.USD","BK4207","LU1969619763.USD","LU0634319403.HKD","BK1583"],"gpt_icon":0},{"id":"2586393022","title":"荣昌生物涨5.43%，东海证券三周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2586393022","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586393022?lang=zh_cn&edition=full","pubTime":"2025-11-26 15:33","pubTimestamp":1764142409,"startTime":"0","endTime":"0","summary":"今日荣昌生物涨5.43%，收盘报92.25元。2025年11月3日，东海证券研究员杜永宏,付婷发布了对荣昌生物的研报《公司简评报告：业绩表现强劲，亏损大幅收窄》，该研报对荣昌生物给出“买入”评级。研报中预计公司2025-2027年实现营业收入23.89/31.74/41.27亿元，归属于母公司净利润-8.75/-3.29/0.88亿元，公司业绩表现强劲，核心产品的商业化能力不断提升，维持“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为浦银国际证券的胡泽宇、阳景。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600017620.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","09995","688331"],"gpt_icon":0},{"id":"2586289514","title":"生物医药股悉数走强 荣昌生物(09995)涨6.65% 机构指医药行业近期震荡调整后估值已回落至相对低位","url":"https://stock-news.laohu8.com/highlight/detail?id=2586289514","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586289514?lang=zh_cn&edition=full","pubTime":"2025-11-26 10:08","pubTimestamp":1764122938,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物医药股悉数走强，截至发稿，荣昌生物 涨6.65%，复宏汉霖涨4.85%，君实生物涨4.43%，康诺亚-B涨4.01%，康方生物涨3.62%，泰格医药涨3.33%，诺诚健华涨3.14%。总体上，2026年预计政策端仍将驱动医药行业腾笼换鸟、创新升级。该机构看好2026年医药行业投资机会，近期震荡调整后估值已回落至相对低位，有望在2026年重启升势，投资思路上寻找医药硬科技和细分赛道α，推荐关注创新药、创新器械、医疗AI方向，关注医药消费复苏及独立第三方ICL。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1970350","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348766576.USD","LU0417516902.SGD","09926","BK1141","IE00B5MMRT66.SGD","01877","LU0348767384.USD","LU0417516571.SGD","BK1161","LU1064130708.USD","688331","BK1583","LU0634319403.HKD","BK1515","161726","BK1587","02696","LU2476274308.USD","LU0540923850.HKD","03347","IE00B543WZ88.USD","LU0348825331.USD","LU0348783233.USD","LU1064131003.USD","02162","LU1969619763.USD","09969","BK1576","LU0561508036.HKD","LU1794554557.SGD","LU1961090484.USD","IE00BPRC5H50.USD","LU2399975544.HKD","LU2476274720.SGD","LU2488822045.USD","LU1720050803.USD","LU2328871848.SGD","BK0239","LU2778985437.USD","09995","LU0417516738.SGD","HK0000165453.HKD","BK1574","LU0348784397.USD","LU0348735423.USD","LU0348827113.USD","LU2148510915.USD","399441"],"gpt_icon":0},{"id":"2585460787","title":"荣昌生物（688331）披露预计2026-2028年度日常关联交易，11月24日股价上涨2.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585460787","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585460787?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:13","pubTimestamp":1763993636,"startTime":"0","endTime":"0","summary":"截至2025年11月24日收盘，荣昌生物报收于88.36元，较前一交易日上涨2.27%，最新总市值为498.09亿元。近日，荣昌生物制药（烟台）股份有限公司发布2025年第三次临时股东会会议资料，宣布将审议《关于预计2026-2028年度日常关联交易的议案》。根据公告，公司预计在2026年至2028年期间与关联方发生采购材料、接受劳务、购买燃料动力、租赁房屋及设备等日常关联交易，三年预计交易总额分别为24,925万元、29,425万元、32,525万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400035365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","BK0239","LU1064130708.USD","LU2328871848.SGD","LU2148510915.USD","09995","LU1969619763.USD","LU1064131003.USD","LU2488822045.USD","688331","BK1161","BK1574"],"gpt_icon":0},{"id":"2585193109","title":"生物医药股全线下跌 荣昌生物(09995)、金斯瑞生物科技(01548)跌超6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585193109","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585193109?lang=zh_cn&edition=full","pubTime":"2025-11-21 11:36","pubTimestamp":1763696200,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物医药股全线下跌，荣昌生物(09995)跌6.42%，金斯瑞生物科技(01548)跌6.3%，复宏汉霖(02696)跌5.77%，康诺亚-B(02162)跌5.24%，药明生物(02269)跌5.16%，泰格医药(03347)跌4.91%，药明康德(02359)跌4.79%，科伦博泰生物-B(06990)跌4.55%，百济神州(06160)跌4.44%，诺诚健华(09969)跌4.44%，君实生物(01877)跌4.40%，再鼎医药(09688)跌4.17%，康方生物(09926)跌3.98%，药明合联(02268)跌3.76%。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250106/MzdhOTliMTI0NzhlMTgxMzU2MzczNzM1NA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/MzdhOTliMTI0NzhlMTgxMzU2MzczNzM1NA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1970077","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162","06990","399441","02696","LU0348766576.USD","LU0516422440.USD","HK0000165453.HKD","LU0572944931.SGD","BK1521","LU0327786744.USD","LU3063872942.SGD","LU0516423174.USD","HK0000320264.USD","LU0348783233.USD","LU0181495838.USD","LU2399975544.HKD","LU0348784397.USD","01877","SG9999014674.SGD","LU0516422366.SGD","BK1610","09926","01548","688331","IE00BPRC5H50.USD","LU0516422952.EUR","LU1064131003.USD","09688","02359","LU0196878994.USD","161726","09995","LU1770034418.SGD","LU2125910500.SGD","BK1587","BK1574","LU0417516902.SGD","09969","02268","06160","LU0140636845.USD","LU0359201612.USD","LU0823426480.USD","LU0456827905.SGD","LU2328871848.SGD","LU1242518931.SGD","LU0456846285.SGD","03347","02269"],"gpt_icon":0},{"id":"2583765626","title":"每周股票复盘：荣昌生物（688331）Q3营收6.2亿环比增8.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583765626","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583765626?lang=zh_cn&edition=full","pubTime":"2025-11-16 01:30","pubTimestamp":1763227826,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，荣昌生物报收于90.08元，较上周的86.94元上涨3.61%。业绩披露要点1、营业收入2025年第三季度营业收入6.2亿元，环比增长8.7%；前三季度实现收入17.2亿元，同比增长42.3%。公司总股本由563,608,243股增至563,710,243股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000209.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688331","09995"],"gpt_icon":0},{"id":"2583563440","title":"荣昌生物（688331）披露2022年A股限制性股票激励计划B类权益预留授予第一个归属期第一次归属结果暨股份上市公告，11月13日股价上涨3.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583563440","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583563440?lang=zh_cn&edition=full","pubTime":"2025-11-13 17:58","pubTimestamp":1763027893,"startTime":"0","endTime":"0","summary":"近日，荣昌生物发布《2022年A股限制性股票激励计划之B类权益预留授予第一个归属期第一次归属结果暨股份上市公告》。公告显示，公司已完成2022年A股限制性股票激励计划B类权益预留授予第一个归属期第一次归属，共向10名激励对象归属102,000股，股票来源为公司向激励对象定向发行A股普通股。公司总股本由563,608,243股增至563,710,243股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251113/31793092.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","09995","BK1161","LU2148510915.USD","LU2328871848.SGD","LU1969619763.USD","BK1583","BK1574","399300","688331","LU1064130708.USD","LU1064131003.USD","LU2488822045.USD","159982"],"gpt_icon":0},{"id":"2583582679","title":"【机构调研记录】诺安基金调研荣昌生物、阿拉丁","url":"https://stock-news.laohu8.com/highlight/detail?id=2583582679","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583582679?lang=zh_cn&edition=full","pubTime":"2025-11-13 08:05","pubTimestamp":1762992349,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及11月12日披露的机构调研信息，诺安基金近期对2家上市公司进行了调研，相关名单如下：1）荣昌生物 调研纪要：2025年第三季度营业收入6.2亿元，环比增长8.7%；前三季度收入17.2亿元，同比增长42.3%。第三季度亏损1.01亿元，前三季度累计亏损5.5亿元，同比减亏48.6%。2）阿拉丁 调研纪要：公司下游覆盖生命科学、半导体、新能源等多个行业，企业端需求恢复较快，叠加高校扩招带动试剂需求上升。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300007167.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1574","LU1064131003.USD","LU2328871848.SGD","BK1583","LU1969619763.USD","BK0239","688179","LU2148510915.USD","BK0216","688331","LU1064130708.USD","LU2488822045.USD","09995"],"gpt_icon":0},{"id":"2581713067","title":"【券商聚焦】浦银国际维持荣昌生物(09995)“持有”评级 指3Q25继续延续此前减亏趋势","url":"https://stock-news.laohu8.com/highlight/detail?id=2581713067","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581713067?lang=zh_cn&edition=full","pubTime":"2025-11-05 10:57","pubTimestamp":1762311461,"startTime":"0","endTime":"0","summary":"金吾财讯 | 浦银国际研报指出，荣昌生物 3Q25实现收入人民币6.2亿元，主要由产品收入贡献，产品收入略好于该机构预期和VA一致预期；归母净亏损进一步缩窄至1.0亿元，略好于该机构预期，但不及VA一致预期，主要由于VA一致预期包含了许可收入预测，而公司表示此前两款BD交易首付款预计今年四季度确认收入。基于该机构的DCF估值模型，该机构得到新的目标价港股75港元，A股人民币96.7元，维持公司“持有”评级。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1969052","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688331","09995"],"gpt_icon":0},{"id":"2580575899","title":"荣昌生物（688331）披露作废部分2022年A股限制性股票激励计划已授予尚未归属的限制性股票，11月4日股价下跌1.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580575899","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580575899?lang=zh_cn&edition=full","pubTime":"2025-11-04 22:25","pubTimestamp":1762266315,"startTime":"0","endTime":"0","summary":"近日，荣昌生物制药（烟台）股份有限公司发布公告称，公司于2025年11月4日召开第二届董事会第三十次会议，审议通过《关于作废部分2022年A股限制性股票激励计划已授予尚未归属的限制性股票的议案》。本次作废事项不影响公司经营、技术及管理团队稳定，亦不影响股权激励计划继续实施。北京海润天睿律师事务所认为，本次作废已履行必要批准程序，作废原因及数量符合相关法律法规及《激励计划》规定，信息披露符合监管要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400039538.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","688331","BK1583","LU2148510915.USD","LU2488822045.USD","LU1064130708.USD","159982","399300","LU1969619763.USD","BK1574","09995","LU2328871848.SGD","BK0239","LU1064131003.USD"],"gpt_icon":0},{"id":"2580315202","title":"小摩：升荣昌生物(09995)目标价至77港元 评级升至中性","url":"https://stock-news.laohu8.com/highlight/detail?id=2580315202","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580315202?lang=zh_cn&edition=full","pubTime":"2025-11-04 15:18","pubTimestamp":1762240683,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，摩根大通发布研报称，下调荣昌生物(09995,688331.SH)2025及26年的产品收入预测，以反映最新业绩，同时上调授权收入预测。随着利润率改善与经营开支减少，该行预期2025及26年净亏损将收窄，因此将H股目标价由73港元升至77港元，评级上调至中性;A股目标价由86元升至92元人民币，维持“中性”评级。该行称，荣昌生物第三季业绩表现参差，期内产品收入低过该行预期，但利润率及经营开支控制好过预期，反映公司持续优化成本。值得注意的是，在6月与VorBio签订RC18授权协议后，公司的研发开支同比下降30%、按季下降24%;行政开支亦下降23%，延续前几季的积极势头。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364954.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688331","09995"],"gpt_icon":0},{"id":"2580751512","title":"交银国际：升荣昌生物(09995)目标价至112港元 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2580751512","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580751512?lang=zh_cn&edition=full","pubTime":"2025-11-04 09:18","pubTimestamp":1762219129,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，交银国际发布研报称，将荣昌生物目标价由109港元升至112港元，维持“买入”评级。报告指，荣昌生物第三季收入保持高增速，亏损收窄。收入同比增长33%至6.2亿元人民币(下同)，其中泰它西普销售收入3.8亿元，同比和按季增长41%和13%;维迪西妥销售收入2.4亿元，同比和按季增长21%和3.5%。管理层表示，有信心实现全年产品销售收入30%以上的增长目标，泰它西普和RC28的BD授权交易首付款收入有望于第四季确认收入。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364817.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09995","688331"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765140262007,"stockEarnings":[{"period":"1week","weight":-0.0326},{"period":"1month","weight":0.0484},{"period":"3month","weight":0.0464},{"period":"6month","weight":0.5811},{"period":"1year","weight":1.6295},{"period":"ytd","weight":2.2033}],"compareEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":-0.0167},{"period":"3month","weight":0.0237},{"period":"6month","weight":0.1529},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1644}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"荣昌生物制药(烟台)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"15248人(较上一季度增加18.39%)","perCapita":"10645股","listingDate":"2022-03-31","address":"山东省烟台市福山区中国(山东)自由贸易试验区烟台片区烟台开发区北京中路58号","registeredCapital":"56371万元","survey":" 荣昌生物制药(烟台)股份有限公司的主营业务是抗体药物偶联物（ADC）、抗体融合蛋白、单抗及双抗等治疗性抗体药物的研发、生产和销售。公司的主要产品是泰它西普、维迪西妥单抗、RC28、RC88、RC148、RC278、RC288。泰它西普发明专利先后获得中国、美国、欧洲等国家和地区的授权，得到了国家“十一五”、“十二五”、“十三五”期间“重大新药创制”科技重大专项支持。","listedPrice":48},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荣昌生物(688331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荣昌生物,688331,荣昌生物股票,荣昌生物股票老虎,荣昌生物股票老虎国际,荣昌生物行情,荣昌生物股票行情,荣昌生物股价,荣昌生物股市,荣昌生物股票价格,荣昌生物股票交易,荣昌生物股票购买,荣昌生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荣昌生物(688331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}